Pathophysiology of Vaginal Atrophy

1. Role of urodynamic testing in differentiating stress vs urgency incontinence

Urodynamic testing is most useful when symptoms overlap, when initial therapy fails, or before invasive treatment. Its value lies in identifying the mechanism of urine loss rather than relying on symptom descriptions alone.

Stress urinary incontinence (SUI)

Pathophysiology

• Urethral sphincter incompetence and/or loss of urethral support
  • Intra-abdominal pressure exceeds urethral closure pressure

Urodynamic findings

• Leakage with increased abdominal pressure (cough, Valsalva)
  • No detrusor contraction at the time of leakage
  • Reduced maximum urethral closure pressure (MUCP)
  • Normal bladder compliance and capacity

Urgency urinary incontinence (UUI)

Pathophysiology

• Detrusor overactivity (neurogenic or myogenic)

• Heightened afferent sensory signaling from bladder/urethra

Urodynamic findings

• Involuntary detrusor contractions during filling cystometry
  • Leakage coincident with detrusor contraction
  • Often reduced bladder capacity
  • Normal urethral function

Why this distinction matters

• SUI —+ pelvic floor therapy, pessaries, surgery
  • UUI -. bladder-directed therapies (behavioral, pharmacologic, hormonal)
  • Mixed incontinence is common, especially postmenopausally, and urodynamics can clarify the dominant component

2. Relationship between urgency incontinence and vaginal atrophy

Urgency incontinence in postmenopausal women is frequently part of the genitourinary syndrome of menopause (GSM) rather than a primary detrusor disorder.

Estrogen deficiency effects

The vagina, urethra, trigone, and bladder neck are all estrogen-responsive tissues.

Loss of estrogen leads to:

• Thinning of urethral and vaginal epithelium
• Reduced glycogen —+ altered microbiome —+ increased inflammation
• Decreased periurethral vascularity
• Reduced alpha-adrenergic receptor density
• Increased sensory nerve excitability

Functional consequences

•       Lower urethral closure pressure

• Increased afferent signaling from urethra and bladder
• Symptoms of urgency, frequency, dysuria, and “urethral syndrome”
• Often normal urine cultures despite irritative symptoms

Importantly, many women labeled as having “overactive bladder” actually have atrophy-driven sensory urgency.

3. Estrogen therapy in urgency incontinence and urethral syndrome Rationale for estrogen treatment

Local estrogen therapy targets the tissue substrate responsible for urgency and irritative symptoms rather than suppressing detrusor contractions pharmacologically.

Mechanisms of action

Local estrogen:

• Restores epithelial thickness and mucosa! integrity
  • Increases urethral vascularity and submucosal coaptation
  • Improves alpha-adrenergic receptor responsiveness
  • Reduces inflammatory cytokine signaling
  • Lowers bladder sensory threshold
  • Enhances local nitric oxide-mediated blood flow

4. Efficacy of local estrogen therapy Urgency and urgency incontinence

Clinical trials and meta-analyses consistently show:

• Reduced urgency episodes
  • Reduced frequency and nocturia
  • Improved bladder capacity
  • Greater benefit in postmenopausal women with GSM features

Local estrogen is most effective when urgency is associated with:

• Vaginal dryness
  • Dysuria without infection
  • Recurrent “UTl-like” symptoms
  • Low urethral closure pressure without detrusor overactivity

Urethral syndrome

Local estrogen is one of the most effective treatments for urethral syndrome, characterized by:

• Dysuria
  • Frequency
  • Urgency
  • Negative cultures

Symptom improvement often occurs within 4-6 weeks.

5. Local estrogen formulations: creams vs tablets

Vaginal estrogen creams (e.g., estradiol, conjugated estrogens)

Advantages

• Broad tissue coverage (vagina + urethra)
  • Adjustable dosing
  • Particularly effective for urethral symptoms

Considerations

• Variable absorption
  • Messier application
  • Higher transient systemic absorption (still low)

Vaginal estrogen tablets (e.g., Vagifem®)

Advantages

• Precise, ultra-low dosing
  • Minimal systemic absorption
  • Excellent safety profile

Efficacy

• Comparable improvement in urgency and frequency
  • Particularly effective for maintenance therapy

Key clinical point

Local estrogen improves urgency and urethral symptoms but does not reliably cure stress incontinence, though it may modestly improve urethral closure pressures.

6. Integration with urodynamic findings

Urodynamic testing helps identify women most likely to benefit from estrogen therapy:

• Normal detrusor activity + low MUCP -+ strong estrogen responders
  • Sensory urgency without detrusor overactivity -+ excellent responders
  • True detrusor overactivity -+ estrogen as adjunct, not primary therapy

7. Summary

• Urodynamics distinguishes mechanical leakage (stress) from detrusor- or sensory-driven urgency
  • Postmenopausal urgency often reflects estrogen deficiency-induced urothelial dysfunction
• Vaginal atrophy plays a central role in urgency and urethral syndrome
  • Localestrogentherapy (creamsortablets) is effective, safe, and pathophysiologically targeted
  • Estrogen restores urethral and bladder sensory stability rather than suppressing bladder contractility

Key Takeaways

• Notelovitz et al. provided pivotal data comparing 10 µg vs 25 µg Vagifem, showing both doses effective at improving signs of vaginal atrophy over ~ 12 weeks.
  • The higher 25 µg dose generally produced greater improvements in clinical and cytological measures compared with the 10 µg dose, although both were beneficial.

LWW Systemic absorption with either dose is low, minimizing broader hormonal effects while targeting local vaginal tissues.    

Resources